Literature DB >> 28131669

"What if I do nothing?" The natural history of operable cancer of the alimentary tract.

H B Keshava1, J E Rosen2, M R DeLuzio3, A W Kim2, F C Detterbeck2, D J Boffa4.   

Abstract

INTRODUCTION: "Natural history", or anticipated survival without treatment, is critical for patients weighing risks and benefits of cancer surgery. Current estimates concerning the natural history of cancer includes patients whose poor health precludes treatment; a cohort whose fate is likely distinctly worse than those eligible for surgery ("operable"). The study objective was to evaluate survival among patients recommended for cancer surgery but went untreated, to determine the natural history of "operable" alimentary tract cancer.
METHODS: The NCDB was queried for untreated patients with clinical stage I-III esophageal, gastric, colon, and rectal cancer diagnosed between 2003 and 2009. Untreated patients who were recommended for surgery were considered "operable," while patients coded as surgically ineligible for health reasons were "inoperable."
RESULTS: 5-year survival of untreated, "operable" alimentary tract cancers varied by clinical stage: esophageal cI = 10.0%, cII = 9.8%, cIII = 4.6%; gastric cI = 9.2%, cII = 5.8%, cIII = 4.3%; colon cI = 18.4%, cII = 5.0%, cIII = 10.4; and rectal cI = 17.1%, cII = 14.0%, cIII = 19.9%. At every timepoint, stage-specific survival of "operable" patients was superior to inoperable patients (p < 0.05). Additionally, median survival among "operable" patients at least doubled "inoperable" patients for each tumor.
CONCLUSION: Natural history of patients with "operable" alimentary tract cancer is superior to that of "inoperable" patients. Preoperative counseling should be refined to reflect this distinction.
Copyright © 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Cancer survival; National Cancer Database; Natural history

Mesh:

Year:  2017        PMID: 28131669     DOI: 10.1016/j.ejso.2016.12.006

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  3 in total

1.  Largely Unchanged Annual Incidence and Overall Survival of Pleural Mesothelioma in the USA.

Authors:  Hari B Keshava; Andrew Tang; Hafiz Umair Siddiqui; Siva Raja; Daniel P Raymond; Alejandro Bribriesco; James Stevenson; Sudish C Murthy; Usman Ahmad
Journal:  World J Surg       Date:  2019-12       Impact factor: 3.352

2.  CRC COVID: Colorectal cancer services during COVID-19 pandemic. Study protocol for service evaluation.

Authors:  Alona Courtney; Ann-Marie Howell; Najib Daulatzai; Nicos Savva; Oliver Warren; Sarah Mills; Shahnawaz Rasheed; Goel Milind; Nicholas Tekkis; Matthew Gardiner; Tinglong Dai; Bashar Safar; Jonathan E Efron; Ara Darzi; Paris Tekkis; Christos Kontovounisios
Journal:  Int J Surg Protoc       Date:  2020-08-11

3.  Proton beam therapy is a safe and effective treatment in elderly patients with esophageal squamous cell carcinoma.

Authors:  Takashi Ono; Hitoshi Wada; Hitoshi Ishikawa; Hiroyasu Tamamura; Sunao Tokumaru
Journal:  Thorac Cancer       Date:  2020-06-08       Impact factor: 3.500

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.